Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 268-277

  Chamat, Soulaima ^a,d   Walsh, Edward E ^c   Anderson, Darrell ^a   Osta, Mike ^d   Awaraji, Christian ^d   Pan, Li Zhen ^a   Ochi, James ^b   Shuey, Steve ^a   Brams, Peter ^a  

^a BIOGEN   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPLEEN CELL; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HN PROTEIN; HUMANS; IMMUNOBLOTTING; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUSES; SPLEEN; TUMOR VIRUS INFECTIONS; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

EID: 0033502732     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314876     Document Type: Article

References (46)

1. 1. Blanchard B. Respiratory syncytial virus infections in children. Arch Pediatr 1994;1:738-45.
2. 2. Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am 1994;41:1365-81.
3. 3. Makela MJ, Ruuskanen O, Ogra PL. Treatment of respiratory syncytial virus in children. Ann Med 1994;26:341-3.
4. 4. Mallol JL, Barrueto G, Girardi, et al. Use of nebulized bronchodilators in infants under 1 year of age; analysis of four forms of therapy. Pediatr Pulmimol 1987;3:298-303.
5. 5. Springer C, Bar-Yshay E, Uwayyed K, et al. Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr Pulmonol 1990;9:181-5.
6. 6. Smith D. Frankel L, Mathers, et al. A controlled trial of aerosolized Ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-9.
7. 7. Chiocca EM. RSV and the high risk infant. Pediatr Nurs 1994;20:565-8.
8. 8. Garcia-Barreno B, Palomo C, Peñas C, Delgado T, Perez-Breña P, Melero JA. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 1989;63:925-32.
9. 9. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
10. 10. Kim HW, Chanchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine or by infection. Am J Epidemiol 1969;89:422-34.
11. 11. Murphy BR, Walsh EE. Formalin inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;26:1595-7.
12. 12. Kakuk TJ, Soike K, Brideau RJ, Zaya RM, Cole SL, Zhang JY, Roberts ED, Wells PA, Wathen MW. A human respiratory syncytial virus primate model of enhanced pulmonary pathology induced with a formalin inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993;167:553-61
13. 13. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin inactivated RSV-immunized Balb/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994;68: 5321-5.
14. 14. Falsey AR, Walsh EE. Safety amd immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997;15:1130-2.
15. HE pathway induced after immunization with a recombinant G protein, BBG2NA, in Aluminum hydroxide. J Infect Dis 1997;176: 560-9.
16. 16. Bastien N, Trudel M, Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology 1997;234: 118-22.
17. 17. Crowe JE, Jr, Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J Infect Dis 1996;173:829-39.
18. 18. Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, Harris WJ. Reshaping a human monoclonal antibody to inhibit human respiratory virus infection in vivo. Biotechnology (NY) 1991;9:266-71.
19. 19. Crowe JE, Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF, III, Burton DR. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91:1386-90.
20. 20. Weltzin R, Traina-Dorge V, Soike K, Zhang JY, Mack P, Soman G, Drabik G, Monath TP. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects Rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996;174:256-61.
21. 21. Tsui P, Tornetta MA, Arnes RS, Bankosky C, Griego, S, Silverman C, Porter T, Moore G, Sweet RW. Isolation of a neutralizing human antibody from a dominant non-neutralizing human antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked planning. J Infect Dis 1996;174:256-61.
22. 21. Ogilve MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibodies and respiratory syncytial virus infection in infancy. J Med Virol 1981;7: 263-71.
23. 23. Hemming VG, Prince GA, Rodriguez W, et al. Respiratory syncytial virus infections and intravenous gamma-globulins. Pediatr Infect Dis J 1988;7 (Suppl.):S103-6.
24. 24. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG. Use of intraveneous gamma globulin to passively immunize high-risk children against respiratory syncytial virus; safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chem-other 1991;35:1469-73.
25. 25. Groothuis JR. The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children. Antiviral Research 1994;23:1-10.
26. 26. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Clin Microbiol Rev 1995;8:22-33.
27. 27. Miller RA, Malloney DG, Killop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981;58:78-86.
28. 28. Shawler, DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-5.
29. 29. Shroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC, Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
30. 30. Brams P, Royston I, Boemer P. In vitro immunization of human lymphocytes; I. IL-2 and IL-4 requirements. Hum Antibodies Hybridomas 1993;4: 47-56.
31. 31. Brams, P, Royston I, Boerner P. In vitro immunization of human lymphocytes: II. Induction of antigen specific IgG responses by repeated antigen stimulation. Hum Antibodies Hybridomas 1993;4:57-65.
32. 32. Lu EW, A. T. Bustria AT, Royston I, Brams O. Factors affecting generation of antibody responses to prostate associated antigens. Hybridoma 1993; 12:381-9.
33. 33. Brams P, Nguyen ML, Chamat S, Royston I, Morrow P. Generation of antigen-specific human IgG responses from naive human splenocytes: m vitro priming followed by antigen boost in the hu-SCID mouse. J Immunol 1998;160:2051-8.
34. 34. Walsh EE, Brandriss MW, Schlesinger J. Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 1985;66: 409-15.
35. 35. Horatinovich JM, Sparks SD, Borowitz MJ. Detection of terminal deoxynucleotidyl transferase by flow cytometry: a three color method. Cytometry 1994;18:228-30.
36. 36. Boerner P, LaFond R, Lu W-Z, Brams P, Royston I. Production of antigen-specific human monoclonal antibodies from in vitro primed human splenocytes. J Immunol 1991;147:86-95.
37. 37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
38. 38. Brams P, Pettijohn DE, Brown, M, Olsson L. In vitro B-lymphocyte antigen priming against both non-immunogenic and immunogenic molecules requiring low amounts of antigen and applicable in hybridoma technology. J Immunol Methods 1987;98:11-22.
39. 39. Anderson LJ, Bingham P, Hierholzer JC, Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 1988;62:4232-8.
40. 40. Streckert HJ, Humbert B, Philippou S, Forster J. Effect of the immune response on the pathogenesis of respiratory syncytial virus (RSV) infection. Immun Infekt 1993;21:75-7.
41. 41. Baiocchi RA, Caligiuri MA. Low-dose interleukine-2 prevents the development of Epstein-Barr virus (EBV)- associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci 1994;91:5577-81.
42. 41 Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model; implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-58.
43. 43. Kozbor D, Roder JC. Requirements for the establishment of high-fitered human monoclonal antibodies against tetanus toxoid using the epstein-barr virus technique. J Immunol 1981;127:1275-80.
44. 44. Heard C, Brams P, Walsh E, Huyenh T, Chamat S, Reff M, Owyang A, Shestowsky W, Newman R. Two neutralizing human anti-RSVantibodies; cloning, expression, and characterization. Mol Med 1999;5:35-45.
45. 45. Barbas CF, III, Crowe JE, Jr, Cababa D, Jones TM, Zebedee SL, Murphy K, Chanock RM, Burton DR. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neuratlize infectivity. Proc Nalt Acad Sci 1992;89:10164-8.
46. 46. Matheise JP, Walravens K, Collard A, Coppe P, Letesson JJ. Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition. Arch Virol 1995;140:993-1005.